MedPath

Hydralazine

Generic Name
Hydralazine
Brand Names
Apresoline, Bidil
Drug Type
Small Molecule
Chemical Formula
C8H8N4
CAS Number
86-54-4
Unique Ingredient Identifier
26NAK24LS8
Background

Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.

Hydralazine hydrochloride was FDA approved on 15 January 1953.

Indication

Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension. A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.

Associated Conditions
Heart Failure, Hypertension, Essential Hypertension, Hypertensive crisis, Severe Hypertension
Clinical Trials
Related News

Hydralazine Investigated as Potential Treatment for Early-Stage Alzheimer's Disease in New Clinical Trial

• A randomized, triple-blind, placebo-controlled trial (EHSAN) is underway to assess hydralazine's efficacy in slowing cognitive decline in mild to moderate Alzheimer's disease (AD) patients. • The trial will enroll 424 participants aged 50 and older with AD, evaluating hydralazine at 75 mg daily over 52 weeks against a placebo, alongside standard AD medications. • Primary outcome is the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog), with secondary measures including daily living activities, neuropsychiatric symptoms, and caregiver burden. • Rigorous monitoring for adverse events, including hypotension and heart failure, will be conducted throughout the trial to ensure patient safety.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy